Research & Scholarship
Continuum's scientific program traces an unbroken chronological arc from 2002 to the present. It opens with the first peer-reviewed randomized, double-blind, placebo-controlled trial to demonstrate efficacy of botanically derived 5-alpha-reductase inhibitors in androgenetic alopecia (Prager, Bickett, French & Marcovici, Journal of Alternative and Complementary Medicine, 2002) — establishing, for the first time, Level-1 clinical evidence for a mechanism-based natural therapy that would seed an entire product category.
Nine years later, in collaboration with the State University of New York's Center for Functional Genomics, that program advanced to whole-genome transcriptomic profiling in human keratinocytes, showing suppression of LPS-activated chemokine and cytokine signaling (Chittur, Parr & Marcovici, Evidence-Based Complementary & Alternative Medicine, 2011) — reframing androgenetic alopecia as, in part, an inflammatory follicular disease.
In 2016, work undertaken with collaborators at the University of Chicago extended these findings into matched dermal-papilla and LNCaP prostate cell assays, where a defined multi-component botanical composition down-regulated androgen-axis biomarkers and outperformed finasteride on those endpoints (Marcovici et al., Phytotherapy Research, 2016).
Four years on, in partnership with Bauman Medical, the program translated this molecular foundation into a nanotechnology-enabled β-cyclodextrin inclusion-complex delivery system — the first reported clinical use of nano-inclusion chemistry to follicularly target a multi-active botanical regimen in androgenetic alopecia (Marcovici & Bauman, Cosmetics, 2020).
Most recently, in joint work with CryoConcepts LP, that nano-botanical platform has been amplified with cryo-chilled, transdermal CO₂ delivery, compressing prior 9-month phenotypic reversal timelines into 90 days even in advanced-stage, historically refractory phenotypes (Niedbala, Campbell, Young & Marcovici, Journal of Complementary Research and Alternative Medicine, 2025).
Across all five landmarks, the work has been conducted in active partnership with university-based investigators and academic medical centers — SUNY's Center for Functional Genomics, the University of Chicago, Columbia University, Bauman Medical, and CryoConcepts LP — coupling industry-driven hypothesis generation with rigorous, independent academic execution.
To date, Continuum's principal investigator has served as an invited expert reviewer for more than 100 manuscripts across over 50 distinct medical sub-specialty journals — spanning dermatology, endocrinology, regenerative medicine, molecular biology, complementary and integrative medicine, cosmetic science, and translational therapeutics.
Review assignments have come from the major scientific publishing houses including Nature Portfolio, Springer, Elsevier, Wiley, and MDPI — reflecting recognition across the breadth of the biomedical literature. A selection of representative titles is shown below.
Verified peer-review activity is recorded on ORCID .
Representative Journals
Cover images shown for editorial identification only; all trademarks and cover artwork remain the property of their respective publishers.
The vast majority of Continuum's published research has been undertaken jointly with investigators based at major university laboratories and academic medical centers. The collaborations below reflect that sustained academic partnership.
University at Albany, State University of New York
Genome-wide expression profiling of inflammatory pathway modulation in human keratinocytes — yielding the 2011 Evidence-Based Complementary & Alternative Medicine publication on suppression of LPS-activated chemokine and cytokine signaling.
Chicago, Illinois
Collaborative development of advanced botanically derived hair restoration formulations, integrating molecular dermatology insights with translational product science.
New York, New York
Scientific exchange and collaboration across investigations relevant to androgen biology, follicular signaling, and translational dermatologic research.
Boca Raton, Florida
Clinical co-investigation of nanotechnology-enabled β-cyclodextrin inclusion complexes in androgenetic alopecia — published in Cosmetics (MDPI, 2020).
Easton, Pennsylvania
Cryo-coupled botanical platform development underpinning the TrichoCyte® formulation system — bridging biophysical chemistry with topical drug-delivery science.
Aurora, Colorado
Co-investigators on the seminal 2002 randomized, double-blind, placebo-controlled trial of botanically derived 5-alpha-reductase inhibitors in androgenetic alopecia — published in the Journal of Alternative and Complementary Medicine.
Original investigation, expert peer review, and university-based collaboration are not separate activities — they are the same body of work, sustained over three decades.